有晶状体人工晶状体
医学
角膜磨镶术
眼科
光折变性角膜切除术
回顾性队列研究
折射误差
视力
外科
作者
Hannuy Choi,Ik Hee Ryu,In Sik Lee,J. Kim,Tae Keun Yoo
出处
期刊:Journal of Cataract and Refractive Surgery
[Ovid Technologies (Wolters Kluwer)]
日期:2023-09-01
卷期号:49 (9): 936-941
被引量:4
标识
DOI:10.1097/j.jcrs.0000000000001246
摘要
Purpose: To compare the postoperative endothelial cell counts of EVO-implantable collamer lenses (ICLs) with a central hole (V4c and V5) and laser vision correction surgery (laser in situ keratomileusis or photorefractive keratectomy). Setting: B&VIIT Eye Center, Seoul, South Korea. Design: Retrospective observational and paired contralateral study. Methods: 62 eyes of 31 patients who underwent EVO-ICLs with a central hole implantation in one eye (phakic intraocular lens [pIOL] group) and laser vision correction in the contralateral eye (LVC group) to correct refractive errors were retrospectively reviewed. Central endothelial cell density (ECD), percentage of hexagonal cells (HEX), coefficient of variation (CoV) in cell size, and adverse events were evaluated for at least 3 years. The endothelial cells were observed using a noncontact specular microscope. Results: All surgeries were performed, without complications during the follow-up period. The mean ECD loss values compared with the preoperative measurements were 6.65% and 4.95% during the 3 years after pIOL and LVC, respectively. There was no significant difference in ECD loss compared with the preoperative values (paired t test, P = .188) between the 2 groups. No significant loss in ECD was observed at any timepoint. The pIOL group showed higher HEX ( P = .018) and lower CoV ( P = .006) values than the LVC group at the last visit. Conclusions: According to the authors' experience, the EVO-ICL with a central hole implantation was a safe and stable vision correction method. Moreover, it did not induce statistically significant changes in ECD at 3 years postoperatively compared with LVC. However, further long-term follow-up studies are required to confirm these results.
科研通智能强力驱动
Strongly Powered by AbleSci AI